Fortress Biotech Inc (NASDAQ: FBIO) on Monday, plunged -8.95% from the previous trading day, before settling in for the closing price of $1.90. Within the past 52 weeks, FBIO’s price has moved between $1.24 and $4.43.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 26.66% over the last five years. The company achieved an average annual earnings per share of 63.40%. With a float of $21.89 million, this company’s outstanding shares have now reached $27.56 million.
The firm has a total of 186 workers. Let’s measure their productivity. In terms of profitability, gross margin is 68.3%, operating margin of -118.39%, and the pretax margin is -85.08%.
Fortress Biotech Inc (FBIO) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Fortress Biotech Inc is 20.58%, while institutional ownership is 14.68%. The most recent insider transaction that took place on Sep 23 ’24, was worth 1,404,581. In this transaction PRESIDENT, CEO & CHAIRMAN of this company bought 763,359 shares at a rate of $1.84, taking the stock ownership to the 3,657,264 shares. Before that another transaction happened on Jul 11 ’24, when Company’s President, CEO & Chairman bought 5,000 for $7.48, making the entire transaction worth $37,418. This insider now owns 127,500 shares in total.
Fortress Biotech Inc (FBIO) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 63.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.50% during the next five years compared to 22.28% growth over the previous five years of trading.
Fortress Biotech Inc (NASDAQ: FBIO) Trading Performance Indicators
Fortress Biotech Inc (FBIO) is currently performing well based on its current performance indicators. A quick ratio of 1.24 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -16.62, a number that is poised to hit -0.59 in the next quarter and is forecasted to reach -1.76 in one year’s time.
Technical Analysis of Fortress Biotech Inc (FBIO)
Analysing the last 5-days average volume posted by the [Fortress Biotech Inc, FBIO], we can find that recorded value of 0.84 million was better than the volume posted last year of 0.38 million. As of the previous 9 days, the stock’s Stochastic %D was 34.98%. Additionally, its Average True Range was 0.13.
During the past 100 days, Fortress Biotech Inc’s (FBIO) raw stochastic average was set at 24.43%, which indicates a significant increase from 7.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.42% in the past 14 days, which was lower than the 74.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7604, while its 200-day Moving Average is $1.8659. Now, the first resistance to watch is $1.9133. This is followed by the second major resistance level at $2.0967. The third major resistance level sits at $2.2033. If the price goes on to break the first support level at $1.6233, it is likely to go to the next support level at $1.5167. Should the price break the second support level, the third support level stands at $1.3333.
Fortress Biotech Inc (NASDAQ: FBIO) Key Stats
Market capitalization of the company is 47.68 million based on 22,814K outstanding shares. Right now, sales total 84,510 K and income totals -60,640 K. The company made 14,900 K in profit during its latest quarter, and -10,950 K in sales during its previous quarter.
